Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
684
datasets available to search
ShareScore release 0.9.0
Dataset results
684 results for “Head and Neck Squamous Cell Carcinoma”
TCGA Head & Neck Squamous Cell Carcinoma (HNSC) Gene Expression
<p><strong>Abstract:</strong></p> <p>The Cancer Genome Atlas (TCGA) was a large-scale collaborative project initiated by the National Cancer Institute (NCI) and the National Human Genome Research Institute (NHGRI). It aimed to comprehensively characterize the genomic and molecular landscape of various cancer types. This dataset contains information about HNSC, a type of cancer that originates in the squamous cells lining the mucosal surfaces of the head and neck region, including the oral cavity, throat, and larynx. The gene expression profile was measured experimentally using the Illumina HiSeq 2000 RNA Sequencing platform by the University of North Carolina TCGA genome characterization center. The Sample IDs serve as unique identifiers for each sample.</p> <p><strong>Inspiration:</strong></p> <p>This dataset was uploaded to UBRITE for GTKB project. </p> <p><strong>Instruction:</strong></p> <p>The log2(x+1) normalization was removed, and z-normalization was performed on the dataset using a Python script.</p> <p><strong>Acknowledgments:</strong></p> <p>Goldman, M.J., Craft, B., Hastie, M. et al. Visualizing and interpreting cancer genomics data via the Xena platform. Nat Biotechnol (2020). https://doi.org/10.1038/s41587-020-0546-8</p> <p>The Cancer Genome Atlas Research Network., Weinstein, J., Collisson, E. et al. The Cancer Genome Atlas Pan-Cancer analysis project. Nat Genet 45, 1113–1120 (2013). https://doi.org/10.1038/ng.2764</p> <p><strong>U-BRITE last update: </strong>07/13/2023</p>
TCGA Head & Neck Squamous Cell Carcinoma (HNSC) Clinical Data
<p><strong>Abstract:</strong></p> <p>The Cancer Genome Atlas (TCGA) was a large-scale collaborative project initiated by the National Cancer Institute (NCI) and the National Human Genome Research Institute (NHGRI). It aimed to comprehensively characterize the genomic and molecular landscape of various cancer types. This dataset includes curated survival data from the Pan-cancer Atlas paper titled <a href="http://www.cell.com/cell/fulltext/S0092-8674(18)30229-0">"An Integrated TCGA Pan-Cancer Clinical Data Resource (TCGA-CDR) to drive high quality survival outcome analytics"</a>. The paper highlights four types of carefully curated survival endpoints, and <a href="http://www.cell.com/action/showFullTableImage?isHtml=true&tableId=tbl3&pii=S0092867418302290">recommends the use of the endpoints of OS, PFI, DFI, and DSS for each TCGA cancer type</a>. The dataset also includes phenotypic information about HNSC. The Sample IDs are unique identifiers, which can be paired with the gene expression dataset. </p> <p><strong>Inspiration:</strong></p> <p>This dataset was uploaded to UBRITE for GTKB project. </p> <p><strong>Instruction:</strong></p> <p>The survival and phenotype data were merged into one file. Empty columns were removed. Columns with the same value for every sample were also removed. </p> <p><strong>Acknowledgments:</strong></p> <p>Goldman, M.J., Craft, B., Hastie, M. et al. Visualizing and interpreting cancer genomics data via the Xena platform. Nat Biotechnol (2020). https://doi.org/10.1038/s41587-020-0546-8</p> <p>Liu, Jianfang, Caesar-Johnson, Samantha J. et al. An Integrated TCGA Pan-Cancer Clinical Data Resource to Drive High-Quality Survival Outcome Analytics. Cell, Volume 173, Issue 2, 400 - 416.e11. <a href="https://doi.org/10.1016/j.cell.2018.02.052">https://doi.org/10.1016/j.cell.2018.02.052</a></p> <p>The Cancer Genome Atlas Research Network., Weinstein, J., Collisson, E. et al. The Cancer Genome Atlas Pan-Cancer analysis project. Nat Genet 45, 1113–1120 (2013). https://doi.org/10.1038/ng.2764</p> <p><strong>U-BRITE last update: </strong>07/13/2023</p>
Data from: External validation of prognostic and predictive gene signatures in 1097 European head and neck squamous cell carcinoma patients
<p><span>Anonymized data containing survival endpoints and gene signature scores for head and neck cancer patients.</span></p> <p><span>File <strong>data_os_gs.csv</strong> : data linking overall survival and gene signature scores</span></p> <p><span>File <strong>data_dfs_gs.csv</strong> : data linking disease-free survival and gene signature scores</span></p> <p><span><strong>Variables</strong>:</span></p> <ul> <li><span><em>supertreat_id</em>: patient ID</span></li> <li><span><em>GS_score_172GS</em>: gene signature score for the <em>172-GS</em> signature. The score is Z-score normalized with a mean of 0 and SD of 1. </span></li> <li><span><em>GS_score_3clustersHPV</em>: gene signature score for the <em>3 clusters HPV</em> signature. The score is Z-score normalized with a mean of 0 and SD of 1. </span></li> <li><span><em>GS_score_RSI</em>: gene signature score for the <em>radiosenstivity index (RSI) </em>signature. The score is Z-score normalized with a mean of 0 and SD of 1. </span></li> <li><span><em>GS_score_pancancerCisplatin</em>: gene signature score for the <em>pancancer-cisplatin</em> signature. The score is Z-score normalized with a mean of 0 and SD of 1. </span></li> <li><span><em>GS_score_cl3Hypoxia</em>: gene signature score for the <em>Cl3-hypoxia</em> signature. The score is Z-score normalized with a mean of 0 and SD of 1. </span></li> <li><span>Variables only available in <strong>data_os_gs.csv: </strong></span> <ul> <li><span><em>overall_survival_days_2years</em>: Overall survival censored at 2 years since diagnosis. Number of days from diagnosis to death or censoring.</span></li> <li><span><em>overall_survival_days_5years</em>: Overall survival censored at 5 years since diagnosis. Number of days from diagnosis to death or censoring.</span></li> <li><span><em>overall_survival_status_2years</em>: Overall survival status when censored at 2 years since diagnosis. Coded as 0 if censored, and 1 if dead. </span></li> <li><span><em>overall_survival_status_5years</em>: Overall survival status when censored at 5 years since diagnosis. Coded as 0 if censored, and 1 if dead. </span></li> </ul> </li> </ul> <ul> <li><span>Variables only available in <strong>data_dfs_gs.csv:</strong></span> <ul> <li><span><em>disease_free_survival_days_2years</em>: Disease-free survival censored at 2 years since diagnosis. Number of days from diagnosis to an event (death or cancer recurrence) or censoring.</span></li> <li><span><em>disease_free_survival_days_5years</em>: Disease-free survival censored at 5 years since diagnosis. Number of days from diagnosis to an event (death or cancer recurrence) or censoring.</span></li> <li><span><em>disease_free_survival_status_2years</em>: Disease-free survival status when censored at 2 years since diagnosis. Coded as 0 if censored, and 1 if an event (death or recurrence). </span></li> <li><span><em>disease_free_survival_status_5years</em>: Disease-free survival status when censored at 5 years since diagnosis. Coded as 0 if censored, and 1 if an event (death or recurrence). </span></li> </ul> </li> </ul>
Patritumab With Cetuximab and a Platinum Agent for Squamous Cell Carcinoma (Cancer) of the Head and Neck (SCCHN )
ClinicalTrials.gov study NCT02633800. IPD Sharing: YES. Countries: 7. Publications: 2.
Sarcopenia index predicts short-term prognosis of head and neck squamous cell carcinoma
<p>Dataset of "Sarcopenia index predicts short-term prognosis of head and neck squamous cell carcinoma"</p>
Re-irradiation With Fractionated Stereotactic Radiosurgery Plus Cetuximab in Patients With Recurrent Squamous Cell Carcinoma of the Head and Neck
ClinicalTrials.gov study NCT01104922. IPD Sharing: NO. Countries: 1. Publications: 1.
Anti-PD-L1/TGF-beta Trap (M7824) Alone and in Combination With TriAd Vaccine and N-803 for Resectable Head and Neck Squamous Cell Carcinoma Not Associated With Human Papillomavirus Infection
ClinicalTrials.gov study NCT04247282. IPD Sharing: YES. Countries: 1. Publications: 3.
Reconstruction of Cervical Lymphatic System During Head and Neck Squamous Cell Carcinoma Surgery
ClinicalTrials.gov study NCT06815705. IPD Sharing: YES. Countries: 1. Publications: 13.
Rapamycin Therapy in Head and Neck Squamous Cell Carcinoma
ClinicalTrials.gov study NCT01195922. IPD Sharing: NO. Countries: 1. Publications: 3.
Screening Trial of Nivolumab With Image Guided, Stereotactic Body Radiotherapy (SBRT) Versus Nivolumab Alone in Patients With Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC)
ClinicalTrials.gov study NCT02684253. IPD Sharing: Not stated. Countries: 1. Publications: 1.
ERBITUX® Followed by Adjuvant Treatment With Chemoradiation and ERBITUX® for Locally Advanced Head and Neck Squamous Cell Carcinoma
ClinicalTrials.gov study NCT01218048. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Cetuximab & Nivolumab in Patients With Recurrent/Metastatic Head & Neck Squamous Cell Carcinoma
ClinicalTrials.gov study NCT03370276. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Study of Cetuximab With Concomitant-boost Radiotherapy in Patients With Newly Diagnosed Locally Advanced Squamous Cell Carcinoma of the Head and Neck (SCCHN)
ClinicalTrials.gov study NCT00865098. IPD Sharing: Not stated. Countries: 1. Publications: 1.
A Phase Ib/II Study of BYL719 and Cetuximab in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
ClinicalTrials.gov study NCT01602315. IPD Sharing: NO. Countries: 9. Publications: 1.
Docetaxel, Cisplatin, and Cetuximab (TPC) in Palliative Treatment of Patients With Squamous Cell Carcinoma of the Head and Neck (SCCHN)
ClinicalTrials.gov study NCT01437449. IPD Sharing: NO. Countries: 1. Publications: 1.
Talimogene Laherparepvec With Pembrolizumab for Recurrent Metastatic Squamous Cell Carcinoma of the Head and Neck (MASTERKEY232 / KEYNOTE-137)
ClinicalTrials.gov study NCT02626000. IPD Sharing: YES. Countries: 11. Publications: 1.
Study in Locally Advanced Squamous Cell Carcinoma of Head and Neck
ClinicalTrials.gov study NCT01133678. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Neoadjuvant Immunochemotherapy and Postoperative Adjuvant Immunotherapy for Head and Neck Squamous Cell Carcinoma Invading the Skull Base
ClinicalTrials.gov study NCT07145931. IPD Sharing: YES. Countries: 1. Publications: 15.
Study of Nivolumab in Combination With Ipilimumab Versus Nivolumab in Combination With Ipilimumab Placebo in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
ClinicalTrials.gov study NCT02823574. IPD Sharing: Not stated. Countries: 21. Publications: 1.
Phase II Study of Skin Toxicity Dosing of IRESSA (Gefitinib) in Squamous Cell Carcinoma of the Head and Neck
ClinicalTrials.gov study NCT00519077. IPD Sharing: Not stated. Countries: 1. Publications: 1.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.